文献速递淋巴瘤

老年弥漫性大B细胞淋巴瘤患者接受R-CHOP治疗的结局:LNH03-6B试验的10年随访

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
PubMed 文献 · Blood Adv · 2022-01-01

LNH03-6B是一项3期随机试验,评估60至80岁、aaIPI评分≥1的弥漫性大B细胞淋巴瘤患者接受每2周或每3周R-CHOP方案(R-CHOP14或R-CHOP21)一线治疗的疗效。中位随访10.1年,10年无进展生存率为40.4%,10年总生存率为50%。在CAR-T细胞治疗时代之前,进展或复发后接受二线化疗的患者预后较差。

要点

  • 10年无进展生存率为40.4%(95%CI 35.9-44.9),10年总生存率为50%(95%CI 43-56)。
  • R-CHOP14组与R-CHOP21组的无进展生存和总生存相似。
  • 首次进展后1年无进展生存2为37.9%(95%CI 31.4-44.5),1年总生存2为55.8%(95%CI 48.8-62.2)。

核心结论

  • 在CAR-T细胞治疗时代之前,弥漫性大B细胞淋巴瘤患者进展或复发后接受二线化疗预后较差。
  • 该人群需要新的一线治疗方法和二线治疗替代方案。

研究设计与样本

  • LNH03-6B是一项3期随机试验,评估每2周或每3周R-CHOP方案(R-CHOP14或R-CHOP21)一线治疗60至80岁、aaIPI评分≥1的弥漫性大B细胞淋巴瘤患者。
  • 304例和296例患者分别被分配接受8个周期的R-CHOP14或R-CHOP21治疗。
  • 对主要分析时仍存活的384例患者中的256例(67%)进行了长期随访数据调查。

主要发现

  • 中位随访10.1年,213例患者进展,140例患者无进展死亡。
  • 10年无进展生存率为40.4%(95%CI 35.9-44.9)。
  • 10年总生存率基于302例死亡,估计为50%(95%CI 43-56)。
  • 在213例患者中,105例(49%)在二线治疗后进展,77例患者(36%)无第二次进展死亡。
  • 1年无进展生存2和1年总生存2分别估计为37.9%(95%CI 31.4-44.5)和55.8%(95%CI 48.8-62.2)。

关键数值与推荐

  • 随机化后10年,R-CHOP14组与R-CHOP21组的无进展生存和总生存相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years with an aaIPI (age-adjusted International Prognostic Index) score ≥1 (registered as NCT00144755). We implemented a prospective long-term follow-up program at the end of this trial. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Relapse patterns, PFS and OS after the first progression (PFS2 and OS2) were secondary endpoints. LNH03-6B was registered with ClinicalTrials.gov #NCT00144755. In the LNH03-6B trial, 304 and 296 patients were assigned to receive 8 cycles of R-CHOP14 or R-CHOP21, respectively. Long-term follow-up data were investigated for 256 of 384 (67%) patients still alive at the primary analysis. With a median follow-up of 10.1 years, 213 patients progressed, and 140 patients died without progression. The 10-year PFS was 40.4% (95% confidence interval, 35.9-44.9). Ten-year OS was based on 302 deaths and estimated at 50% (43-56). Of the 213 patients, 105 (49%) progressed after second-line therapy, and 77 patients died without a second progression (36%). The 1-year PFS2 and 1-year OS2 were estimated at 37.9% (95% confidence interval, 31.4-44.5) and 55.8% (95% confidence interval, 48.8-62.2), respectively. Ten years after randomization, the outcomes of patients treated for DLBCL were similar according to PFS and OS between the RCHOP-14 and R-CHOP21 groups. Progression or relapse led to poor prognosis after second-line chemotherapy in the pre CAR-T-cell era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Camus V, Belot A, Oberic L, et al. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022. PMID: 35737565. doi:10.1182/bloodadvances.2022007609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。